ArticlePharmaceutical research2026
NIPTE 2030: The Nation's Digital Trust Anchor for Pharma 5.0.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the National Institute for Pharmaceutical Technology and Education (NIPTE) marks its 20th anniversary, the pharmaceutical ecosystem faces a widening gap between regulatory "risk-to-quality" compliance and real-world "risk-to-patient" outcomes. This Perspective offers a strategic roadmap for NIPTE to address the ontological fragmentation that treats drug products as legal descriptors rather than engineered systems. We suggest NIPTE is uniquely positioned to serve as the nation's "digital trust anchor" for Pharma 5.0-a human-centric evolution toward a patient-sovereign paradigm. By championing a five-layer CMC-GraphRAG architecture, NIPTE can lead the transition toward "Ontological Honesty" -defined here as the systematic grounding of AI reasoning in complete, mechanistically accurate representations of drug products and manufacturing processes as engineered systems. This choice allows NIPTE to elevate the patient's voice, transforming subjective experiences into mechanistically grounded Real-World Evidence (RWE). We illustrate these possibilities through the SMART-TDS pilot, which provides the scientific foundation-measured by the Semantic Precision Score (SPS) and Uncertainty Quantification (UQ)-necessary to support future industry-wide transitions toward dynamic, patient-centric quality assurance.
Indexed as
Identifiers
42141172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.